Related Experiment Video
Updated: Aug 1, 2026
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Complete response of metastatic renal cancer with dendritic cell vaccine
Marcos Dall'Oglio1, Miguel Srougi, José A M Barbuto
1Discipline of Urology, Paulista School of Medicine, Federal University of São Paulo, UNIFESP, Sírio Libanês Hospital of São Paulo and Department of Immunology, ICB-USP, São Paulo, SP, Brazil. marcosdalloglio@uol.com.br
Introduction:
We report a case of metastatic renal cell carcinoma that presented involution following therapy with dendritic cells.
Case Report:
Male, 51-year old patient underwent left radical nephrectomy in September 1999 due to renal cell carcinoma, evolved with recurrence of the neoplasia in January 2002, confirmed by resection of the lesion. A vaccine therapy based on dendritic cells was then performed during 5 months (4 applications). After this period, there was occurrence of new lesions, whose resection revealed areas of necrosis and inflammatory infiltrate.
Discussion:
The outcome of renal cell carcinoma is influenced by prognostic factors that confer more aggressive tumor characteristics. However, in cases of recurrence, the systemic therapy with dendritic cells-based vaccine can be associated with a better outcome with regression of disease.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...